the $130-$210 is based on only 1 indication being approved (with the other 3 all failing). This valuation range is taken from the earlier analysis I posted with the $130-$210 basically being one-quarter the valuation for all indications being approved. The $130 is the lower end Daybue value + 3xpeak sales and $210 is the upper end of the Daybue value + 4.8x peak sales. I was pointing out that if all Ph IIs are successful then its reasonable to value Neuren on the basis that at least one of the indications can be expected to get approval. Or put another way, although Ph III still represents a risk, because there are 4 indications this means the worst case risk is quite low and therefore if all Ph II's are positive Neuren should be valued at that point (perhaps end of this year) as if NNZ-2591 is an approved drug (for at least 1 indication).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)